The company's unique approach to structuring financing has created a robust channel for investors and philanthropists to support genetic disease drug development, and for BridgeBio to continue to target multiple different indications at once," added Dr. Stephenson. The article was co-authored by Dr. Lo and members of BridgeBio senior management, including Dr. Kumar, Dr. Stephenson and Dr. Chinmay Shukla, Vice President, Strategic Finance. About BridgeBio Pharma, Inc. BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials.